Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Capillary Sampling in Clinical Populations Undergoing Monitoring (CAPSICUM)

28 de agosto de 2026 atualizado por: University of Edinburgh

Many people with long-term health conditions require regular blood tests to monitor their disease or medications. These blood tests are usually performed by taking blood from a vein during a hospital or clinic appointment. This can be inconvenient, time-consuming and difficult for some people, particularly those who live far from hospital, have reduced mobility, require frequent tests, or experience anxiety about attending healthcare settings or having blood taken.

Capillary blood sampling devices allow people to collect a small blood sample themselves, usually from the upper arm or fingertip, which can then be sent to a laboratory by post. These devices have shown promising results for some blood tests, but there is insufficient evidence of which tests remain accurate when samples are collected at home, posted to the laboratory and subjected to postage conditions and delayed analysis.

The CAPSICUM study will compare blood samples collected using patient-operated capillary sampling devices with routine venous blood samples already being taken as part of participants' usual clinical care. We will investigate whether a wide range of blood tests produce similar results using both methods and assess how delayed analysis, postal transport and home collection affect test accuracy.

Participants will attend only one study visit, which will take place during a routine clinic appointment. Some participants will also be invited to collect an additional blood sample at home and return it by post, and to complete a brief questionnaire about their experience.

The findings from this study will help identify which blood tests can be safely monitored using home capillary blood sampling. This could improve access to blood monitoring, reduce unnecessary hospital visits, make monitoring more convenient for patients, and support the development of safe, evidence-based remote monitoring pathways within the NHS.

Visão geral do estudo

Tipo de estudo

Observacional

Inscrição (Estimado)

1000

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Richard Shemilt, MBChB
  • Número de telefone: +441312427978
  • E-mail: rshemilt@ed.ac.uk

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Filho
  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Método de amostragem

Amostra Não Probabilística

População do estudo

A maximum of 1000 participants will be recruited. The study aims to include approximately 200 participants from each of five clinical populations in which regular blood monitoring forms part of routine care and where remote capillary blood sampling has the potential to improve access to monitoring or patient experience:

  • Patients with kidney disease
  • Patients with immune-mediated disease
  • Kidney, kidney-pancreas and islet transplant recipients
  • Patients with mental health disorders requiring regular blood monitoring
  • Children attending paediatric services who require regular blood monitoring

Descrição

Inclusion Criteria:

Eligible participants are individuals who require routine venous blood sampling as part of their usual clinical care and who represent clinical populations in which remote capillary blood sampling may improve access to monitoring or patient experience.

All participants must:

  • Be attending a routine clinical appointment during which venous blood sampling is planned as part of standard clinical care for disease monitoring or therapeutic drug monitoring.
  • Be willing and able to undertake capillary blood sampling independently or with appropriate assistance.

Adult participants must:

  • Be aged ≥18 years of age.
  • Have capacity to provide written informed consent.

Paediatric participants must:

  • Be aged 6-15 years of age.
  • If aged 6-11, be attending with a parent or legal guardian able to provide written informed consent and provide age-appropriate assent where applicable.
  • If aged 12-15: be attending with a parent or legal guardian able to provide written informed consent and provide age-appropriate assent where applicable OR if deemed to have capacity themselves, be able to provide written informed consent and be attending with a parent or legal guardian who agrees to their participation.

Additional eligibility criteria

Autoimmune disease group: participants must have a diagnosis of immune-mediated disease based on the assessment of their treating clinician.

Transplant recipient group: participants must be the recipient of a functioning kidney, kidney-pancreas, or islet transplant.

Mental health group: participants must have a diagnosis of a mental health disorder based on the assessment of their treating clinician.

Paediatric group: participants must be attending a paediatric clinic and require blood sampling as part of standard clinical care.

Exclusion Criteria:

  • Inability or unwillingness to provide informed consent, or, for paediatric participants, absence of parental or legal guardian consent or age-appropriate assent where applicable.
  • Skin disease, infection, injury, or other local factors at the intended sampling site that would make capillary blood collection unsafe or impractical.
  • Known allergy or hypersensitivity to any materials used in the capillary blood sampling devices.
  • Inability to undertake the capillary sampling procedures independently or with appropriate assistance.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

Coortes e Intervenções

Grupo / Coorte
Intervenção / Tratamento
Patients with kidney disease
Blood sampling with capillary sampling device(s)
Patients with immune-mediated disease
e.g. ANCA-associated vasculitis or systemic lupus erythematosus
Blood sampling with capillary sampling device(s)
Kidney, kidney-pancreas and islet transplant recipients
Blood sampling with capillary sampling device(s)
Patients with mental health disorders who experience barriers to conventional blood sampling
Blood sampling with capillary sampling device(s)
Children requiring regular blood monitoring
Blood sampling with capillary sampling device(s)

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Prazo
For each pre-defined analyte, the mean difference and 95% limits of agreement between paired capillary and venous blood sample results under immediate analysis conditions, assessed against predefined clinically acceptable limits of agreement.
Prazo: From enrollment to end of study visit 1
From enrollment to end of study visit 1

Medidas de resultados secundários

Medida de resultado
Prazo
Mean difference and 95% limits of agreement following delayed analysis (24-48 hours).
Prazo: From enrollment to end of study visit 1
From enrollment to end of study visit 1
Mean difference and 95% limits of agreement following delayed analysis after exposure to temperatures representative of routine postal transport.
Prazo: Enrollment to end of study visit 1
Enrollment to end of study visit 1
Mean difference and 95% limits of agreement following unsupervised patient-led home collection and postal return.
Prazo: Enrollment to end of study visit 1
Enrollment to end of study visit 1
Proportion of successful capillary sample collections and proportion of samples unsuitable for laboratory analysis, by analyte, patient group and sampling device.
Prazo: Enrollment to end of study visit 1
Enrollment to end of study visit 1
Reasons for unsuccessful sample collection or laboratory rejection, where available
Prazo: Enrollment to end of study visit 1
Enrollment to end of study visit 1
Participant acceptability, pain, ease of use and overall preference for capillary sampling compared with venepuncture, assessed using validated questionnaires.
Prazo: Enrollment to end of study visit 1
Enrollment to end of study visit 1

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de outubro de 2026

Conclusão Primária (Estimado)

30 de setembro de 2029

Conclusão do estudo (Estimado)

30 de setembro de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

28 de agosto de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

28 de agosto de 2026

Primeira postagem (Real)

3 de setembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

3 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

28 de agosto de 2026

Última verificação

1 de agosto de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever